LIVIVO - Search results -

Search results

Result 1 - 10 of total 56

Search options

Article ; Online: Multiethnic myeloma.

Weiss, Brendan M

2013 Volume 121, Issue 16, Page(s) 3062–3064

MeSH term(s)	African Americans/genetics ; Genomics/methods ; Humans ; Immunoglobulin Heavy Chains/genetics ; Multiple Myeloma/genetics ; Translocation, Genetic
Chemical Substances	Immunoglobulin Heavy Chains
Language	English
Publishing date	2013-04-17
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2013-03-487215
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The authors reply.

Hogan, Jonathan J / Weiss, Brendan M / Dember, Laura M

Kidney international

2019 Volume 95, Issue 2, Page(s) 468

MeSH term(s)	Glomerulonephritis ; Humans
Language	English
Publishing date	2019-01-21
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	120573-0
ISSN	1523-1755 ; 0085-2538
ISSN (online)	1523-1755
ISSN	0085-2538
DOI	10.1016/j.kint.2018.11.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 797: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

Hogan, Jonathan J / Weiss, Brendan M

Clinical journal of the American Society of Nephrology : CJASN

2016 Volume 11, Issue 9, Page(s) 1681–1691

Abstract: The monoclonal gammopathies of renal significance (MGRS) are a group of disorders characterized by monoclonal Ig deposition in the kidney, but are not associated with systemic lymphoma or overt multiple myeloma. The prevailing hypothesis is that the ... ...

Abstract	The monoclonal gammopathies of renal significance (MGRS) are a group of disorders characterized by monoclonal Ig deposition in the kidney, but are not associated with systemic lymphoma or overt multiple myeloma. The prevailing hypothesis is that the pathogenic paraproteins in MGRS are produced by underlying B cell or plasma cell clones. However, in the MGRS literature, the yield of detecting a clone has been variable, and progression to ESRD is common. Here, we present an "onco-nephrologic" approach to the MGRS disorders by highlighting recent advances in lymphoma and multiple myeloma that can be used in the evaluation and management of these patients.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bendamustine Hydrochloride/administration & dosage ; Bortezomib/administration & dosage ; Cyclophosphamide/administration & dosage ; Dexamethasone/administration & dosage ; Humans ; Immunoglobulins/metabolism ; Immunosuppressive Agents/therapeutic use ; Kidney Diseases/drug therapy ; Kidney Diseases/etiology ; Kidney Diseases/metabolism ; Lenalidomide ; Melphalan/administration & dosage ; Oligopeptides/administration & dosage ; Paraproteinemias/complications ; Paraproteinemias/diagnosis ; Paraproteinemias/drug therapy ; Pentostatin/administration & dosage ; Rituximab/administration & dosage ; Thalidomide/analogs & derivatives ; Thalidomide/therapeutic use ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives
Chemical Substances	Immunoglobulins ; Immunosuppressive Agents ; Oligopeptides ; Pentostatin (395575MZO7) ; Rituximab (4F4X42SYQ6) ; Thalidomide (4Z8R6ORS6L) ; Bortezomib (69G8BD63PP) ; carfilzomib (72X6E3J5AR) ; Dexamethasone (7S5I7G3JQL) ; Cyclophosphamide (8N3DW7272P) ; Bendamustine Hydrochloride (981Y8SX18M) ; Lenalidomide (F0P408N6V4) ; Vidarabine (FA2DM6879K) ; fludarabine (P2K93U8740) ; Melphalan (Q41OR9510P)
Language	English
Publishing date	2016-07-14
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2226665-3
ISSN	1555-905X ; 1555-9041
ISSN (online)	1555-905X
ISSN	1555-9041
DOI	10.2215/CJN.03160316
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6584: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: AA amyloidosis associated with Castleman disease: A case report and review of the literature.

Bernabei, Luca / Waxman, Adam / Caponetti, Gabriel / Fajgenbaum, David C / Weiss, Brendan M

Medicine

2020 Volume 99, Issue 6, Page(s) e18978

Abstract: Rationale: AA amyloidosis (AA) is caused by a wide variety of inflammatory states, but is infrequently associated with Castleman disease (CD). CD describes a heterogeneous group of hematologic disorders that share characteristic lymph node ... ...

Abstract	Rationale: AA amyloidosis (AA) is caused by a wide variety of inflammatory states, but is infrequently associated with Castleman disease (CD). CD describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. CD can present with a solitary enlarged lymph node (unicentric CD, UCD) or with multicentric lymphadenopathy (MCD), constitutional symptoms, cytopenias, and multiple organ dysfunction due to an interleukin-6 driven cytokine storm. Patient concerns: We are reporting a case of a 26-year-old woman with no significant past medical history who presented with a 3-month history of fatigue and an unintentional 20-pound weight loss. Diagnosis: A CT-scan of the abdomen and pelvis revealed hepatosplenomegaly and a mesenteric mass. Congo Red staining from a liver biopsy showed apple-green birefringence and serum markers were suggestive of an inflammatory process. Post-excision examination of the resected mass revealed a reactive lymph node with follicular hyperplasia with kappa and lambda stains showing polyclonal plasmacytosis consistent with CD. Interventions: The patient underwent surgery to remove the affected lymph node. Outcomes: IL-6, anemia, leukocytosis, and thrombocytosis resolved or normalized 2 weeks after resection; creatinine normalized 9 months postsurgery. Twenty two months post-surgery her IFN-γ normalized, her fatigue resolved, her proteinuria was reduced by >90% and she had returned to her baseline weight. Lessons: Our case and literature review suggest that patients presenting with UCD or MCD along with organ failure should prompt consideration of concurrent AA amyloidosis.
MeSH term(s)	Adult ; Amyloidosis/blood ; Amyloidosis/diagnosis ; Amyloidosis/diagnostic imaging ; Amyloidosis/etiology ; Castleman Disease/blood ; Castleman Disease/complications ; Castleman Disease/diagnosis ; Fatigue/etiology ; Female ; Humans ; Peritoneal Diseases/blood ; Peritoneal Diseases/diagnosis ; Peritoneal Diseases/diagnostic imaging ; Peritoneal Diseases/etiology ; Serum Amyloid A Protein/analysis ; Tomography, X-Ray Computed ; Weight Loss
Chemical Substances	Serum Amyloid A Protein
Language	English
Publishing date	2020-03-19
Publishing country	United States
Document type	Case Reports ; Journal Article ; Review
ZDB-ID	80184-7
ISSN	1536-5964 ; 0025-7974
ISSN (online)	1536-5964
ISSN	0025-7974
DOI	10.1097/MD.0000000000018978
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.

Hester, Laura L / Gifkins, Dina M / M Bellew, Kevin / Vermeulen, Jessica / Schecter, Jordan M / Strony, John / Dishy, Victor / Weiss, Brendan M

European journal of haematology

2021 Volume 107, Issue 4, Page(s) 428–435

Abstract: Light-chain (AL) amyloidosis is a multisystem disorder with a high early mortality and diagnostic delays of >1 year from symptom onset. This retrospective observational study sought to characterize the clinical prodrome and diagnostic delay to inform ... ...

Abstract	Light-chain (AL) amyloidosis is a multisystem disorder with a high early mortality and diagnostic delays of >1 year from symptom onset. This retrospective observational study sought to characterize the clinical prodrome and diagnostic delay to inform early detection. We identified 1523 adults with newly diagnosed AL amyloidosis in the Optum de-identified Clinformatics
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Arrhythmias, Cardiac/diagnosis ; Arrhythmias, Cardiac/physiopathology ; Databases, Factual ; Delayed Diagnosis ; Dyspnea/diagnosis ; Dyspnea/physiopathology ; Edema/diagnosis ; Edema/physiopathology ; Fatigue/diagnosis ; Fatigue/physiopathology ; Female ; Humans ; Immunoglobulin Light-chain Amyloidosis/diagnosis ; Immunoglobulin Light-chain Amyloidosis/physiopathology ; Male ; Middle Aged ; Paraproteinemias/diagnosis ; Paraproteinemias/physiopathology ; Prodromal Symptoms ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/physiopathology ; Retrospective Studies ; Time-to-Treatment/statistics & numerical data
Language	English
Publishing date	2021-07-23
Publishing country	England
Document type	Journal Article ; Observational Study
ZDB-ID	392482-8
ISSN	1600-0609 ; 0902-4441
ISSN (online)	1600-0609
ISSN	0902-4441
DOI	10.1111/ejh.13679
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 323: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.

Weiss, Brendan M / Wong, Sandy W / Comenzo, Raymond L

Blood

2016 Volume 127, Issue 19, Page(s) 2275–2280

Abstract: Systemic immunoglobulin light chain (LC) amyloidosis (AL) is a potentially fatal disease caused by immunoglobulin LC produced by clonal plasma cells. These LC form both toxic oligomers and amyloid deposits disrupting vital organ function. Despite ... ...

Abstract	Systemic immunoglobulin light chain (LC) amyloidosis (AL) is a potentially fatal disease caused by immunoglobulin LC produced by clonal plasma cells. These LC form both toxic oligomers and amyloid deposits disrupting vital organ function. Despite reduction of LC by chemotherapy, the restoration of organ function is highly variable and often incomplete. Organ damage remains the major source of mortality and morbidity in AL. This review focuses on the challenges posed by emerging therapies that may limit the toxicity of LC and improve organ function by accelerating the resorption of amyloid deposits.
MeSH term(s)	Amyloidosis/diagnosis ; Amyloidosis/metabolism ; Amyloidosis/pathology ; Amyloidosis/therapy ; Humans ; Immunoglobulin Light Chains/metabolism ; Plasma Cells/metabolism ; Plasma Cells/pathology
Chemical Substances	Immunoglobulin Light Chains
Language	English
Publishing date	2016-02-23
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2015-11-681650
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.

Gertz, Morie A / Landau, Heather J / Weiss, Brendan M

American journal of hematology

2016 Volume 91, Issue 12, Page(s) E506–E508

MeSH term(s)	Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Humans ; Immunoglobulin Light-chain Amyloidosis/drug therapy ; Immunoglobulin Light-chain Amyloidosis/pathology ; Male ; Middle Aged
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; NEOD001 (VXQ2SK8I3P)
Language	English
Publishing date	2016-10-21
Publishing country	United States
Document type	Case Reports ; Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	196767-8
ISSN	1096-8652 ; 0361-8609
ISSN (online)	1096-8652
ISSN	0361-8609
DOI	10.1002/ajh.24563
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1251: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Impact of metformin on the progression of MGUS to multiple myeloma.

Boursi, Ben / Mamtani, Ronac / Yang, Yu-Xiao / Weiss, Brendan M

Leukemia & lymphoma

2016 Volume 58, Issue 5, Page(s) 1265–1267

MeSH term(s)	Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Case-Control Studies ; Disease Progression ; Humans ; Incidence ; Metformin/pharmacology ; Metformin/therapeutic use ; Monoclonal Gammopathy of Undetermined Significance/drug therapy ; Monoclonal Gammopathy of Undetermined Significance/epidemiology ; Monoclonal Gammopathy of Undetermined Significance/pathology ; Multiple Myeloma/epidemiology ; Multiple Myeloma/pathology ; Odds Ratio ; Population Surveillance ; Protective Agents/pharmacology ; Protective Agents/therapeutic use ; United Kingdom/epidemiology
Chemical Substances	Antineoplastic Agents ; Protective Agents ; Metformin (9100L32L2N)
Language	English
Publishing date	2016-10-05
Publishing country	United States
Document type	Letter ; Research Support, N.I.H., Extramural
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.1080/10428194.2016.1236375
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Weiss, Brendan M / Kuehl, W Michael

Expert review of hematology

2010 Volume 3, Issue 2, Page(s) 165–174

Abstract: Monoclonal gammopathy of undetermined significance (MGUS) affects at least 3% of the population above the age of 50 and is the precursor to multiple myeloma (MM), an incurable malignancy of plasma cells. Recent advances in MGUS include: an improved ... ...

Abstract	Monoclonal gammopathy of undetermined significance (MGUS) affects at least 3% of the population above the age of 50 and is the precursor to multiple myeloma (MM), an incurable malignancy of plasma cells. Recent advances in MGUS include: an improved understanding of the pathogenesis of MGUS and its progression to MM, involving molecular events intrinsic to the malignant plasma cell as well as the microenvironment; novel techniques to assess risk for progression to MM using serum-free light-chain analysis and immunophenotyping; and a renewed interest in chemoprevention of MM. In the future, continued improvement in our understanding of MGUS will lead to the development of better biomarkers for prognosis and therapies for chemoprevention of MM.
MeSH term(s)	Humans ; Immunoglobulin Light Chains/blood ; Immunophenotyping ; Models, Biological ; Multiple Myeloma/diagnosis ; Multiple Myeloma/etiology ; Multiple Myeloma/therapy ; Paraproteinemias/diagnosis ; Paraproteinemias/pathology ; Paraproteinemias/therapy ; Risk Factors ; ras Proteins/genetics ; ras Proteins/metabolism
Chemical Substances	Immunoglobulin Light Chains ; ras Proteins (EC 3.6.5.2)
Language	English
Publishing date	2010-05-16
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Intramural ; Review
ZDB-ID	2516804-6
ISSN	1747-4094 ; 1747-4086
ISSN (online)	1747-4094
ISSN	1747-4086
DOI	10.1586/ehm.10.13
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6943: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.

Minnema, Monique C / Dispenzieri, Angela / Merlini, Giampaolo / Comenzo, Raymond L / Kastritis, Efstathios / Wechalekar, Ashutosh D / Grogan, Martha / Witteles, Ronald / Ruberg, Frederick L / Maurer, Mathew S / Tran, NamPhuong / Qin, Xiang / Vasey, Sandra Y / Weiss, Brendan M / Vermeulen, Jessica / Jaccard, Arnaud

JACC. CardioOncology

2022 Volume 4, Issue 4, Page(s) 474–487

Abstract: Background: Patients with amyloid light chain amyloidosis and severe cardiac dysfunction have a poor prognosis. Treatment options that induce rapid and deep hematologic and organ responses, irrespective of cardiac involvement, are needed.: Objectives!# ...

Abstract	Background: Patients with amyloid light chain amyloidosis and severe cardiac dysfunction have a poor prognosis. Treatment options that induce rapid and deep hematologic and organ responses, irrespective of cardiac involvement, are needed. Objectives: The aim of this study was to evaluate the impact of baseline cardiac stage on efficacy and safety outcomes in the phase 3 ANDROMEDA trial. Methods: Rates of overall complete hematologic response and cardiac and renal response at 6 months and median major organ deterioration-progression-free survival and major organ deterioration-event-free survival were compared across cardiac stages (I, II, or IIIA) and treatments (daratumumab, bortezomib, cyclophosphamide, and dexamethasone [D-VCd] or bortezomib, cyclophosphamide, and dexamethasone [VCd]). Rates of adverse events (AEs) were summarized for patients with and without baseline cardiac involvement and by cardiac stage. Results: Median follow-up duration was 15.7 months. The proportions of stage I, II, and IIIA patients were 23.2%, 40.2%, and 36.6%. Across cardiac stages, hematologic and organ response rates were higher and major organ deterioration-progression-free survival and major organ deterioration-event-free survival were longer with D-VCd than VCd. AE rates were similar between treatments and by cardiac stage; serious AE rates were higher in patients with cardiac involvement and increased with increasing cardiac stage. The incidence of cardiac events was numerically greater with D-VCd vs VCd, but the rate of grade 3 or 4 events was similar. The exposure-adjusted incidence rate for cardiac events was lower with D-VCd than VCd (median exposure 13.4 and 5.3 months, respectively). Conclusions: These findings demonstrate the efficacy of D-VCd over VCd in patients with newly diagnosed amyloid light chain amyloidosis across cardiac stages, thus supporting its use in patients with cardiac involvement. (NCT03201965).
Language	English
Publishing date	2022-11-15
Publishing country	United States
Document type	Journal Article
ISSN	2666-0873
ISSN (online)	2666-0873
DOI	10.1016/j.jaccao.2022.08.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED